新冠二價疫苗認受性低 專家呼籲華人勿被誤導

Latest Content

The AAPI Vote in 2026: What Has Shifted Within This Diverse Electorate?

Oct 15 | Explore how Asian American and Pacific Islander voters’ priorities are shifting ahead of the 2026 midterms, including new survey findings, Gen Z engagement, voting barriers, and perspectives from battleground states.

A Former TPS Holder Navigates San Francisco’s Matrix of Surveillance Cameras

Losing TPS in 2025 stripped Samir of his work, his income, and the life he built. It also left him feeling exposed to an expanding surveillance network.

Author Related

00:59:17

Can Prop 1 Mitigate California’s Housing Crisis?

Oct 13 | California voters will weigh Proposition 1, an $11.25 billion housing bond funding affordable housing, homeownership, farmworker housing and veterans’ programs amid the state’s deep housing affordability crisis this November election.
00:58:43

The Native Vote in 2026: Sovereignty, Representation and Political Power

Native voters head into the 2026 midterms focused on sovereignty, representation, voting access and political power as Indigenous communities navigate distinct priorities across reservations, rural areas and cities.

Sing Tao Daily

Headline: Experts Urge Continued Vigilance as Vaccination Rates Plummet

The Centers for Disease Control recently announced bivalent vaccination rates for the new coronavirus, with just 16% of people nationwide having received the new vaccine and 21% among Asian Americans. In San Francisco, the city’s bivalent vaccination rate is 39%, and 41% among Asian Americans.

These numbers are far below early vaccination rates which topped out at nearly 90%.

Our interviews revealed that there are many reasons preventing the Asian community from receiving the bivalent vaccine, including concerns about side effects, the spread of disinformation on Chinese social media, fatigue caused by prolonged resistance to the vaccine, and a relaxed vigilance against the virus.

Professionals are urging the Chinese community to learn to identify reliable sources of information and to get vaccinated as early as possible.

The current U.S. bivalent vaccine, developed for Omicron BA4 and BA5, is currently available from Pfizer and Moderna, and is available free of charge at pharmacy chains in major supermarkets. However, since the launch of the bivalent vaccine last September, enthusiasm for the vaccine has been much lower than that for the earlier vaccines as the spread of the virus has slowed in San Francisco and the state of emergency for the new strains of Coronavirus has been lifted.

Experts and health care providers say those conditions present potential hazards as the virus is still out there and continues to spread among the public.

Read the full story at Sing Tao Daily (Chinese version only)